Real-world comparison of cabazitaxel vs. 177-lutetium-PSMA radioligand therapy in metastatic castration resistant prostate cancer.

被引：0
|
作者：
Wenzel, Mike
Koll, Florestan
Hoeh, Benedikt
Humke, Clara
Siech, Carolin
Mader, Nicolai
Groener, Daniel
Steuber, Thomas
Graefen, Markus
Maurer, Tobias
Brandts, Christian H.
Banek, Severine
Chun, Felix
Mandel, Philipp
机构：
[1] Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Dept Nucl Med, Frankfurt, Germany
[4] Goethe Univ Frankfurt, Dept Nucl Med, Frankfurt, Germany
[5] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[6] Prostate Canc Ctr Hamburg, Martini Clin, Hamburg, Germany
[7] Goethe Univ Frankfurt, Frankfurt, Germany
[8] Goethe Univ Frankfurt, Dept Urol, Frankfurt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.70
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
    Aggarwal, Piyush
    Gunasekaran, Vinisha
    Sood, Ashwani
    Kumar, Narendra
    Rathore, Yogesh
    Kumar, Rajender
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (03) : 231 - 233
  • [32] Radioligand Therapy with 177Lu-PSMA in Metastatic Castration Resistant Prostate Cancer Patients: First case series in Iran
    Aryana, K.
    Moghadam, S. Zarehparvar
    Divband, G. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S649 - S650
  • [33] Antitumor activity of repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Braeuer, Axel
    Yordanova, Anna
    Boegemann, Martin
    Hauser, Stefan
    Eveslage, Maria
    Essler, Markus
    Schafers, Michael
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [34] CLINICAL EXPERIENCE WITH LUTETIUM 177-LABELED PSMA-I&T FOR RADIOLIGAND THERAPY IN 100 CONSECUTIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Heck, Matthias
    Schwaiger, Sebastian
    Knorr, Karina
    Retz, Margitta
    Maurer, Tobias
    Janssen, Friederike
    D'Alessandria, Calogero
    Wester, Hans-Juergen
    Gschwend, Juergen
    Schwaiger, Markus
    Tauber, Robert
    Eiber, Matthias
    JOURNAL OF UROLOGY, 2018, 199 (04): : E304 - E304
  • [35] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
  • [36] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [37] Extended radioligand therapy with Lu-177-PSMA-617 in patients with advanced metastatic castration-resistant prostate cancer
    Mader, N.
    Baumgarten, J.
    Groener, D.
    Ngoc, C. Nguyen
    Davis, K.
    Banek, S.
    Tselis, N.
    Happel, C.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S489 - S489
  • [38] Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial
    Ardolino, Luke C.
    Dear, Rachel
    Armstrong, Andrew J.
    Gillessen, Silke
    Joshua, Anthony M.
    EUROPEAN UROLOGY, 2023, 84 (04) : E94 - E95
  • [39] Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial
    Morris, Michael J.
    Sartor, Oliver
    de Bono, Johann S.
    Fizazi, Karim
    Tagawa, Scott T.
    EUROPEAN UROLOGY, 2023, 84 (01) : 7 - 8
  • [40] Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT)
    Bergstrom, Colin P.
    Song, Hong
    Ruiz, Shann Mika
    Chien, Joanne
    Moore, Kaidi
    Parikh, Divya Ahuja
    Shah, Sumit
    Fan, Alice C.
    Srinivas, Sandy
    Iagaru, Andrei
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 86 - 86
12345